Subclinical Atherosclerosis Noted in Diffuse Scleroderma PDF Print E-mail
Saturday, 15 September 2012 14:29
Patients with diffuse systemic sclerosis (SSc), without any clinical evidence of cardiovascular disease, have indicators of subclinical atherosclerosis, according to a study published online Aug. 16 in Arthritis Care & Research.

To identify signs of early cardiovascular involvement in SSc, Maurizio Turiel, M.D., of the University of Milan, and colleagues conducted a pilot study involving 20 patients with diffuse SSc but no signs of cardiovascular disease, and 20 age- and gender-matched control patients. The researchers found that arterial wall measurements were significantly different in SSc versus control patients.

Compared with controls, in SSc patients, right and left carotid intima-media thickness, pulse wave velocity, and stiffness index β were also significantly elevated. Coronary flow reserve was significantly lower and plasma levels of asymmetric dimethylarginine levels were significantly higher in those with SSc compared with healthy controls. "In conclusion, patients with diffuse SSc seem to have subclinical cardiovascular involvement, as demonstrated by various methods," the authors write. "Further studies are required to define more precise algorithms for assessing and managing cardiovascular disease in SSc patients."

Source: Healthday (2012), "Subclinical Atherosclerosis Noted in Diffuse Scleroderma"; Original article can be viewed here.

 
More articles :

» Adult Stem Cells Are Helping Scleroderma Patients

Dr. Richard Burt and colleagues at Northwestern University have just published a new study in that provides more evidence for the success of adult stem cell transplant in treating System Sclerosis ().Ten patients were treated with their own adult...

» The Clinical Relevance of Autoantibodies in Scleroderma

Khanh T Ho and John D ReveillePublished: 12 February 2003Arthritis Res Ther 2003, 5:80-93 (DOI 10.1186/ar628)© 2003 BioMed Central Ltd (Print ISSN 1478-6354; Online ISSN 1478-6362)Scleroderma (systemic sclerosis) is associated with several...

» Basal Activation of Type I Interferons (Alpha2 and Beta) and 2'5'OAS Genes

Danilo Bretas de Oliveira, Gabriel Magno de Freitas Almeida, Antonio Carlos Martins Guedes, Flavia Patrıcia Sena Teixeira Santos, Claudio Antonio Bonjardim, Paulo Cesar Peregrino Ferreira, and Erna Geessien KroonReceived 15 June 2011; Revised 10...

» Clinical Manifestations of Heart Disease In Autoimmune Disorders

Dr. Lawrence Phillips is the Assistant Professor of Medicine, Division of Cardiology and Director of Nuclear Cardiology at the . At the recently concluded , Dr. Phillips presented on the clinical manifestations of heart diseases in autoimmune...

» L-selectin and Skin Damage in Systemic Sclerosis

L-selectin ligands are induced on the endothelium of inflammatory sites. L-selectin expression on neutrophils and monocytes may mediate the primary adhesion of these cells at sites of inflammation by mediating the leukocyte-leukocyte interactions...

» Interferons As A Potential Treatment For Scleroderma

A variety of new treatments are being currently investigated and developed for the treatment of Systemic in hopes of better controlling symptoms and slowing the progression of the disease. Once such treatment is Interferons, in which recent studies...